Rituxan is sold through a joint venture between Genentech and Biogen-Idec (nasdaq: BIIB - news - people ).
She and Rauch both point out that Elan is a lot more likely to benefit from Antegren sales than Biogen-Idec (nasdaq: BIIB - news - people ), which may have to cannibalize sales of its existing MS treatment Avonex to sell Antegren.
Tysabri, the multiple sclerosis drug made by Biogen-Idec and Elan, was pulled from the market for increasing the risk of deadly brain infection.
Indeed, there are a few of these on his list such as T-MD1 for breast cancer (Roche), alpharadin for prostate cancer (Bayer) and BG-12 for MS (Biogen-Idec).
One interesting case is Biogen-Idec (BIIB) which built a huge campus at the intersection of Route 128 and Route 20 in the tony suburb of Weston while maintaining a research facility in Cambridge.
FORBES: How MIT's Kendall Square Attracted $2 Billion And So Can You
Genentech (nyse: DNA - news - people ) and Biogen Idec (nasdaq: BIIB - news - people ) said Tuesday that a key study of the drug Rituxan did not meet its main goal of a response in patients with systemic lupus erythematosus, commonly called lupus.
Investors immediately threw a party for Elan (nyse: ELN - news - people ) and its marketing partner Biogen Idec (nasdaq: BIIB - news - people ).
In late 1997 the FDA approved Rituxan, made by San Diego-based idec Pharmaceuticals Corp.
He also thinks that many fund managers, including himself, will want to offload their stakes in IDEC (nasdaq: IDPH - news - people ) or Biogen (nasdaq: BGEN - news - people ) to keep from owning too much of the combined company, dubbed Biogen IDEC.
"If pharma doesn't do it anymore, somebody else has got to do it, " says Rainer Fuchs, a vice president at Biogen Idec who runs its in-house biotech incubator.
Lofty expectations for its multiple sclerosis drug Antegren, to be co-marketed with Biogen Idec, have caused shares to quadruple this year.
Today Biogen Idec (BIIB) reported top-line results of EMPOWER, a Phase 3 trial investigating dexpramipexole in people with amyotrophic lateral sclerosis (ALS).
The trial of Genentech and Biogen Idec (nasdaq: BIIB - news - people )'s lymphoma drug, Rituxan, in diabetes progression could report results later this year.
Teva makes Copaxone, a treatment for multiple sclerosis that competes with the MS drugs made by Biogen Idec (nasdaq: BIIB - news - people ) and Serono.
"These things don't get immediately disentangled, " says Church, who worked in the medical biotech business as a researcher in the early days of Biogen, now part of Biogen Idec (nasdaq: BIIB - news - people ), before coming to Harvard.
Since taking over at ImClone, he's installed one director from his own firm and two others that may be friendly to him, including a Harvard Medical School professor Icahn also nominated for the board of Biogen Idec (nasdaq: BIIB - news - people ) when he sought to take control there.
In the meantime, a similar drug from IDEC Pharmaceuticals (nasdaq: IDPH - news - people ) reached the market.
It was developed and is co-promoted by Genentech and IDEC Pharmaceuticals.
Rituxan, the cancer drug sold by Genentech and IDEC Pharmaceuticals (nasdaq: IDPH - news - people ), is already being tested for the same disease.
Biogen Idec Inc. ( BIIB - news - people ), experienced sharp upward shifts in share price as well as in options implied volatility following the news.
The most successful offspring is Idec Pharmaceuticals (nasdaq: IDPH - news - people ), which, with help from Genentech, developed Rituxan, a monoclonal antibody for non-Hodgkin's lymphoma.
Elan and Biogen IDEC are submitting to the FDA based on a one-year analysis of a two-year study.
Some of the world's biggest drug and biotech firms are entering the once-neglected field, including Novartis, Biogen Idec and Merck.
The company, formed by the not-very-successful 2003 combination of Biogen and rival Idec, draws its revenues from three main drugs.
Biogen Idec and Genentech are fighting over the rights to the Rituxan-like drug and have entered arbitration.
Adding Biogen Idec would graft labs in California and Massachusetts to this just-created construct, or else shift them into a parallel research and development operation Pfizer is just starting to build from close to scratch out of San Francisco.
Meanwhile IDEC has been the subject of constant merger speculation because it gets 30% of sales from top-selling cancer drug Rituxan, which is co-marketed with Genentech (nyse: DNA - news - people ).
Working with Yale University neurologist Stephen Strittmatter, who cloned the Nogo gene, Biogen Idec has created a counterinsurgency protein that acts as a sponge to soak up copies of Nogo and other growth-blocking proteins in the spinal cord before they can bind to the receptor.
应用推荐